Asset Publisher


Clinical trial of new drug for chronic Chagas disease

Phase II multicenter, randomized, placebo-controlled study of the safety and efficacy of three oral dosing regimens of E1224 and benznidazole in adult patients with chronic indeterminate Chagas disease

E1224 is a prodrug of ravuconazole developed by Eisai Pharmaceuticals. It is administered orally and has been shown to have potent activity against the parasite responsible for Chagas disease. It also has several other properties that make it a promising candidate for the treatment of Chagas disease, including good absorption and tolerability profiles, once-weekly administration, and an affordable price.

The drug is being tested in a phase II study conducted by ISGlobal, in conjunction with the Platform for the Integral Care of Patients With Chagas Disease, a collaborative project involving CEADES (a Bolivian NGO), Universidad Mayor de San Simón de Cochabamba, and Universidad Autónoma Juan Misael Saracho (Tarija). This phase II proof-of-concept study will analyse the potential of E1224 as an oral, easy-to-use, safe, and affordable treatment for Chagas disease. The project is being coordinated by the Drugs for Neglected Diseases Initiative and funded by the Wellcome Trust.

The study will also investigate several biomarkers that may help to assess disease cure and treatment success in patients with chronic Chagas disease and serve as valuable tools in future clinical trials of E1224 and other new drugs. The current lack of early markers of treatment response is a major obstacle in the fight against Chagas disease.

Enlaces de interés

Our Team

Our Team

  • Quim Gascon
    Quim Gascon Research Professor, Director of the Chagas Initiative

Other projects

See Past Projects


New Tools for the Diagnosis and Evaluation of Chagas Disease

RTS,S Vaccine Immunology Study

Study of immune correlates of protection against malaria after vaccination with RTS,S/AS01E: a comprehensive immunological arm of a Phase III double-blind, randomized, controlled multi-center trial

Control of Leishmaniasis. From bench to bedside and community


Grup de recerca en patología importada i malaties emergents i re-emergents


New chemotherapy regimens and biomarkers for Chagas Disease


Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults


Malaria mass and focal drug administration to advance malaria elimination in Mozambique: accelerating programmatic implementation and policy translation


MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention


Citizens engagement digital platform for collective intelligence in pandemics


Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria


Building Scalable Pathogen Genomic Epidemiology in Ethiopia


Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test


Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses


P. falciparum genomic intelligence in Mozambique


Broad One Health Endectocide-based Malaria Intervention in Africa


Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum


Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria


Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria


Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.


Social affairs and sex in P. falciparum: implications for malaria elimination

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy


Sharing knowledge and catalyzing research towards a malaria-free world